Moderate versus ultra-hypofractionated locoregional breast radiotherapy: Results of a retrospective study during the covid-19 era.

Purpose: The use of ultra hypofractionated adjuvant breast radiotherapy for elderly patients was extended during the covid-19 pandemic. We compared its efficacy and safety versus moderate hypofractionation in elderly patients with breast cancer receiving locoregional radiotherapy at a single radiotherapy centre.

Methods: This retrospective analysis utilized routine patient data.

Cascade of immunologic adverse events related to pembrolizumab treatment.

Immune checkpoint inhibitors, such as pembrolizumab, have significantly improved cancer patient outcome. Toxicities are usually moderate and manageable. However, some adverse events, if not early recognised, could be life-threatening.